Citations 1
Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.
Yoon, Harry H. , Bendell, Johanna C. , Braiteh, Fadi S., Firdaus, Irfan , Philip, Philip Agop, Cohn, Allen Lee, Lewis, Nancy , Anderson, D. Mark , Arrowsmith, Edward, Schwartz, Jonathan D. , Xu, Yihuan, Koshiji, Minori, Anderson, Daniel M., Alberts, Steven R. , Wainberg, Zev A.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4004-4004
